Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
systane + cyclosporine
- Development stage
- Unknown
- Lead developer
- Allergan
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
Systane + cyclosporine is a combination therapy used for the management of dry eye disease. Systane is an ocular lubricant (artificial tear) that provides symptomatic relief by moisturizing and protecting the ocular surface, while cyclosporine is an immunomodulatory agent that increases tear production by reducing ocular surface inflammation. Cyclosporine acts as a calcineurin inhibitor, suppressing T-cell mediated inflammation in the lacrimal glands and conjunctiva, thereby improving natural tear production. This combination leverages both immediate lubrication from Systane and long-term anti-inflammatory effects from cyclosporine to address both symptoms and underlying causes of dry eye disease[1][2][3][5].
- Other names
- systane + cyclosporine
02
Targets
PPIF (Cyclophilin D)CN (Calcineurin)Cyp (Cyclophilin family)
Beyond the preview
Go deeper on systane + cyclosporine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on systane + cyclosporine.